Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Oryon shines out of stealth with $21M to fight Parkinson's
Oryon Cell Therapies is launching with a $21 million series A round and announcing that physician entrepreneur Ron Cohen, M.D., will be its CEO.
Will Maddox
Mar 23, 2026 5:00am
Aspen's Parkinson's cell therapy data plant seeds for ph. 3
Mar 18, 2026 9:00am
Biohaven reduces scope of R&D cuts as pipeline progresses
Mar 3, 2026 9:00am
Insilico agrees to $66M deal to split rights for NLRP3 inhibitor
Jan 21, 2026 7:05am
Lilly buys inflammation biotech Ventyx for $1.2B
Jan 8, 2026 7:01am
Hope springs toward Parkinson's phase 3 despite divergent data
Dec 23, 2025 9:00am
